Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A

NCT03095287 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.

NCT NCT03095287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03095287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A
Lead sponsor
Grifols Therapeutics LLC
Phase
Phase 2
Overall status
Terminated
Start date
January 3, 2018
Completion date
September 18, 2020
Enrollment
2 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, congenital